<DOC>
	<DOCNO>NCT01698879</DOCNO>
	<brief_summary>Acute myeloid leukemia ( AML ) neoplasm immature hematopoietic cell ( blast ) alter ripen capacity . Due excessive proliferation , blast displace normal hematopoietic cell bone marrow failure appear . Leukemic cell also infiltrate extramedullary tissue . Following standard chemotherapy treatment , CR rate achieve around 65-75 % patient 15 % low consider patient 65 year . Modifications standard regimen consist replace DNR cytotoxic one , modify dose ara-C add third drug . Gemtuzumab ozogamicin ( Mylotarg ® ) immunoconjugate anti-CD33 antibody cytotoxic antitumor antibiotic , calicheamicin . Mylotarg ® antibody specifically bind CD33 , sialic acid-dependent adhesion protein express 90 % LMA10 . Mylotarg ® selectively transport cytotoxic agent calicheamicin leukemic cell hematopoietic progenitor differentiate myelomonocytic line , respect pluripotent hematopoietic stem cell . Calicheamicin release fixation antibody anti-CD33 internalization cell , bind damage DNA . Mylotarg ® approve U.S. treatment CD33 positive AML first relapse , patient older 60 year non-candidates intensive treatment modality . Since efficacy Mylotarg ® equivalent toxicity profile less conventional therapy , logical conduct phase II trial explore role Mylotarg ® early stage treatment AML . Previous experience gemtuzumab ozogamicin relapse patient lead use combine induction chemotherapy . The aim improve CR rate reach latter reduce relapse achieve great leukemic cytoreduction . Recent data HOVON group support administration G-CSF induction chemotherapy decrease incidence relapse patient AML , particularly consider intermediate risk . Everything mention justifies investigate combination GO combine chemotherapy IDR ara-C standard 3x7 scheme analyze effect sensitization G-CSF patient AML de novo . If treatment propose effective present acceptable toxicity investigate .</brief_summary>
	<brief_title>Prospective Study Mylotarg G-CSF Acute Myeloid Leukemia Treatment</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Gemtuzumab</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<criteria>1 . Patients primary `` de novo '' AML , different promyelocytic M3 subtype . 2 . Age 18 70 year . 3 . Written inform consent form 1 . Acute leukemia appear myeloproliferative process myelodysplastic syndrome longer 6 month , AML arise another cure malignant disease ( e.g . Hodgkin 's disease ) , secondary AML treat alkylating agent radiation . 2 . Acute promyelocytic leukemia . 3 . Relevant history liver disease . Significant impair liver function ( bilirubin , AST ALT ≥ 2.5 time normal value ) attributable leukemic infiltration . 4 . Patients prior heart failure . 5 . Symptomatic chronic respiratory failure . 6 . Positive serology HIV , hepatitis C virus surface antigen . 7 . Estimated life expectancy le 3 month , despite treatment . 8 . Pregnancy breastfeed time inclusion study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>